GB Sciences (GBLX) 10-Q 2 Sep 20 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2020	Sep. 01, 2020
Document Information [Line Items]
Entity Registrant Name	GB SCIENCES INC
Entity Central Index Key	0001165320
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		280,532,686
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 101,230	$ 151,766
Accounts receivable, net of allowance for doubtful accounts of $126,650 and $130,378 at June 30, 2020 and March 31, 2020, respectively	192,509	117,967
Inventory, net	1,545,891	1,445,839
Prepaid expenses and other current assets	57,057	60,885
Note receivable	5,224,423	5,224,423
TOTAL CURRENT ASSETS	7,121,110	7,000,880
Property and equipment, net	5,360,299	5,533,833
Intangible assets, net of accumulated amortization of $15,344 and $12,287 at June 30, 2020 and March 31, 2020, respectively	1,776,045	1,699,966
Deposits and other noncurrent assets	91,504	91,504
Operating lease right-of-use assets, net	24,684	26,685
TOTAL ASSETS	14,373,642	14,352,868
CURRENT LIABILITIES:
Accounts payable	2,712,122	2,559,914
Accrued interest	654,760	397,652
Accrued liabilities	1,188,938	888,012
Notes and convertible notes payable and line of credit, net of unamortized discount of $247,695 and $608,580 at June 30, 2020 and March 31, 2020, respectively	6,327,113	5,534,728
Indebtedness to related parties	712,176	586,512
Note payable to related party	151,923	151,923
Income tax payable	601,822	592,982
Finance lease obligations, current	146,211	166,769
Operating lease obligations, current	7,579	7,265
TOTAL CURRENT LIABILITIES	12,502,644	10,885,757
Operating lease obligations, long term	20,499	22,515
Finance lease obligations, long term	3,499,612	3,533,090
TOTAL LIABILITIES	16,022,755	14,441,362
Commitments and contingencies (Note 8)
STOCKHOLDERS' EQUITY:
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 280,532,686 and 275,541,602 outstanding at June 30, 2020 and March 31, 2020, respectively	28,054	27,554
Additional paid-in capital	97,574,001	97,271,157
Accumulated deficit	(99,251,168)	(97,387,205)
TOTAL EQUITY/(DEFICIT)	(1,649,113)	(88,494)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)	$ 14,373,642	$ 14,352,868

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 126,650	$ 130,378
Intangible assets, accumulated amortization	$ 15,344	12,287
Notes and convertible notes payable, unamortized discount, current
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	280,532,686	275,541,602
Common stock, shares outstanding (in shares)	280,532,686	275,541,602

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Sales revenue	$ 551,197	$ 910,676
Cost of goods sold	(491,795)	(624,369)
Gross profit	59,402	286,307
General and administrative expenses	804,708	2,065,549
LOSS FROM OPERATIONS	(745,306)	(1,779,242)
OTHER EXPENSE
Interest expense	(795,313)	(437,815)
Debt default penalty	(286,059)
Other expense	(11,182)
Total other expense	(1,092,554)	(437,815)
LOSS BEFORE INCOME TAXES	(1,837,860)	(2,217,057)
Income tax expense	(8,840)	(57,392)
LOSS FROM CONTINUING OPERATIONS	(1,846,700)	(2,274,449)
Loss from discontinued operations		(264,434)
NET LOSS	(1,846,700)	(2,538,883)
Loss attributable to non-controlling interest		(132,216)
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	(1,846,700)	(2,406,667)
Continuing operations	(1,846,700)	(2,274,449)
Discontinued operations		(132,218)
Net loss	$ (1,846,700)	$ (2,406,667)
Continuing operations (in dollars per share)	$ (0.01)	$ (0.01)
Discontinued operations (in dollars per share)
Net loss (in dollars per share)	$ (0.01)	$ (0.01)
Weighted average common shares outstanding - basic and diluted (in shares)	277,968,516	244,036,524

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited)	3 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
OPERATING ACTIVITIES:
Net loss	$ (1,846,700)	$ (2,538,883)
Loss from discontinued operations		(264,434)
Net loss from continuing operations	(1,846,700)	(2,274,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,028	99,485
Stock-based compensation		176,402
Bad debt expense/(recovery)	(3,728)	51,344
Amortization of debt discount and beneficial conversion feature	510,885	200,382
Interest expense on conversion of notes payable		17,225
Default penalty on convertible note payable	286,059
Changes in operating assets and liabilities:
Accounts receivable	(70,814)	126,579
Prepaid expenses and other current assets	3,828	192,733
Decrease in deposits and other noncurrent assets		8,762
Inventory	64,602	(311,887)
Accounts payable	72,280	(222,008)
Accrued expenses	264,662	100,887
Accrued interest	247,549	86,719
Income tax payable	8,840
Indebtedness to related parties	125,664
Net cash used in operating activities of continuing operations	(323,845)	(1,747,826)
Net cash used in operating activities of discontinued operations		(883,295)
Net cash used in operating activities	(323,845)	(2,631,121)
INVESTING ACTIVITIES:
Purchase of property and equipment		(170,647)
Acquisition of intangible assets		(39,027)
Net cash used in investing activities of continuing operations		(209,674)
Net cash used in investing activities of discontinued operations		(48,000)
Net cash used in investing activities		(257,674)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock		745,975
Proceeds from warrant exercises	151,202
Proceeds from convertible notes payable	150,000	2,500,000
Proceeds from line of credit	5,000
Fees for issuance of convertible note		(175,000)
Brokerage fees for issuance of common stock and warrants	(15,121)	(91,104)
Principal payments on debt and lease obligations	(17,772)	(62,641)
Net cash provided by financing activities of continuing operations	273,309	2,917,230
Net cash used in financing activities of discontinued operations		(114,881)
Net cash provided by financing activities	273,309	2,802,349
Net change in cash and cash equivalents	(50,536)	(86,446)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	151,766	227,758
CASH AND CASH EQUIVALENTS AT END OF PERIOD	101,230	141,312
Less: cash and cash equivalents classified as discontinued operations		(107,738)
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	101,230	33,574
Cash paid for interest
Cash paid for income tax
Non-cash transactions:
Depreciation capitalized in inventory	164,654
Property capitalized under operating leases		213,218
Patent filing and drafting costs capitalized in intangible assets	78,226
Discount on convertible notes payable attributable to warrant modification	150,000
Stock issued upon conversion of long-term note payable		170,000
Induced dividend from warrant exercises	17,263	74,400
Cumulative effect of the new lease standard		$ 7,551

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Noncontrolling Interest [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Mar. 31, 2019						240,627,102
Balance (Accounting Standards Update 2016-02 [Member]) at Mar. 31, 2019			$ (7,551)		$ (7,551)
Balance at Mar. 31, 2019						$ 24,063	$ 93,020,015	$ (84,743,836)	$ 8,855,757	$ 17,155,999
Issuance of stock for debt conversion (in shares)						1,000,000
Issuance of stock for debt conversion						$ 100	169,900			170,000
Exercise of warrants for stock (in shares)						1,957,500
Exercise of warrants for stock						$ 196	175,979			176,175
Share based compensation expense							176,402			176,402
Issuance of stock for cash, net of issuance costs (in shares)						3,668,167
Issuance of stock for cash, net of issuance costs						$ 367	478,329			478,696
Exchanged shares issued to consultant for options (in shares)						(400,000)
Exchanged shares issued to consultant for options						$ (40)	40
Inducement dividend from warrant exercises							74,400	(74,400)
Net loss								(2,406,667)		(2,406,667)
Loss attributable to non-controlling interest									(132,216)	(132,216)
Balance (in shares) at Jun. 30, 2019						246,852,769
Balance at Jun. 30, 2019						$ 24,686	94,095,065	(87,232,454)	8,723,541	15,610,838
Balance (in shares) at Mar. 31, 2020						275,541,602
Balance at Mar. 31, 2020						$ 27,554	97,271,157	(97,387,205)		(88,494)
Exercise of warrants for stock (in shares)						4,991,084
Exercise of warrants for stock						$ 500	135,581			136,081
Inducement dividend from warrant exercises							17,263	(17,263)
Net loss								(1,846,700)		(1,846,700)
Loss attributable to non-controlling interest
Discount on convertible notes payable attributable to warrant modification							150,000			150,000
Balance (in shares) at Jun. 30, 2020						280,532,686
Balance at Jun. 30, 2020						$ 28,054	$ 97,574,001	$ (99,251,168)		$ (1,649,113)

Note 1 - Background and Signifi

Note 1 - Background and Significant Accounting Policies	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 1 GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) seeks to be a biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets. The Company is engaged in the research and development of cannabinoid medicines and plans to produce cannabinoid therapies for the wellness markets based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of cannabinoid medicines with virtual operations in North America and Europe. GBSGB assets include cannabinoid medicine intellectual property, research contracts and key supplier arrangements. GBSGB's intellectual property covers a range of conditions and several programs are in pre-clinical animal stage of development; including Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB's intellectual property portfolio includes two five four one 2020, three 28 We were incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On March 13, 2014, April 4, 2014, Effective December 12, 2016, 8 October 14, 2016. Effective April 8, 2018, 250,000,000 400,000,000. August 15, 2019, 400,000,000 600,000,000. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2021. March 31, 2020 not 10 March 31, 2020 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts to conform to the current period presentation. Certain items on the unaudited statements of operations and cash flows have been reclassified to conform with current period presentation. The assets, liabilities, income, and cash flows of GB Sciences Louisiana, LLC have been separated from the comparative period amounts to confirm to the current period presentation as discontinued operations as the result of the sale of the Company's interest in GB Sciences Louisiana, LLC (Note 10 no Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. There were no June 30, 2020 March 31, 2020 The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three June 30, 2020 2019 For the Three Months Ended June 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 551,197 $ - $ 551,197 $ 910,676 $ - $ 910,676 Cost of goods sold (491,795 ) - (491,795 ) (624,369 ) - (624,369 ) Gross profit 59,402 - 59,402 286,307 - 286,307 General and administrative expenses 804,708 - 804,708 2,065,549 201,840 2,267,389 LOSS FROM OPERATIONS (745,306 ) - (745,306 ) (1,779,242 ) (201,840 ) (1,981,082 ) OTHER EXPENSE Interest expense (795,313 ) - (795,313 ) (437,815 ) (62,594 ) (500,409 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense (11,182 ) - (11,182 ) - - - Total other expense (1,092,554 ) - (1,092,554 ) (437,815 ) (62,594 ) (500,409 ) LOSS BEFORE INCOME TAXES (1,837,860 ) - (1,837,860 ) (2,217,057 ) (264,434 ) (2,481,491 ) Income tax expense (8,840 ) - (8,840 ) (57,392 ) - (57,392 ) NET LOSS $ (1,846,700 ) $ - $ (1,846,700 ) $ (2,274,449 ) $ (264,434 ) $ (2,538,883 ) Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not No June 30, 2020 Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not Earnings/(loss) per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 153,412,936 158,404,020 June 30, 2020 March 31, 2020 not Recent Accounting Pronouncements Recently Adopted Standards In June 2016, No. 2016 13, 326 2016 13" 326 326 326 2016 13 not not December 15, 2022, In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, April 1, 2020. not All other newly issued accounting pronouncements but not not

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 The Company's financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $ ( 99,251,168 June 30, 2020 ( 5,381,534 June 30, 2020 ( 3,884,877 March 31, 2020 ( 323,845 three June 30, 2020 ( 2,631,121 ( 883,295 three June 30, 2019 Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not may

Note 3 - Inventory

Note 3 - Inventory	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 3 Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. June 30, 2020 March 31, 2020 Raw materials $ 129,133 $ 91,465 Work in progress 923,737 $ 1,166,511 Finished goods 619,491 $ 466,319 Subtotal 1,672,361 1,724,295 Allowance to reduce inventory to net realizable value (126,470 ) (278,456 ) Total inventory, net $ 1,545,891 $ 1,445,839

Note 4 - Leases

Note 4 - Leases	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Lessee, Operating and Finance Leases [Text Block]	Note 4 The Company determines if an arrangement is a lease at inception and has lease agreements for warehouses, office facilities, and equipment. These commitments have remaining non-cancelable lease terms, with lease expirations which range from 2024 2025. As a result of the adoption of ASC 842, $182,624, $190,173 April 1, 2019, Operating leases are included in other current assets , accrued liabilities, and operating lease obligations, long term on the unaudited condensed consolidated balance sheets. Finance leases are included in property and equipment, finance lease obligations, short term, and finance lease obligations, long term, on the unaudited condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% 11.5%. 17.0%. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not During the three June 30, 2020 $143,599, $104,924 $38,675 $3,243, $1,242 $2,001 Amortization of lease assets is included in general and administrative expenses. The future minimum lease payments of lease liabilities as of June 30, 2020 Year Ending Operating March 31, Finance Leases Leases 2021 (9 months) $ 422,801 $ 8,836 2022 544,296 11,779 2023 560,625 11,779 2024 577,444 3,926 2025 594,767 - Thereafter 3,781,101 - Total minimum lease payments 6,481,034 36,320 Less: Amount representing interest (2,835,211 ) (8,242 ) Present value of minimum lease payments 3,645,823 28,078 Less: Current maturities of capital lease obligations (146,211 ) (7,579 ) Long-term capital lease obligations $ 3,499,612 $ 20,499

Note 5 - Notes Payable and Line

Note 5 - Notes Payable and Line of Credit	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 0% October 23, 2017 On October 23, 2017, 100% 100% one $500,000 0% $700,000 three January 1, 2018. The present value of the note was $521,067 20.3% $178,933. three June 30, 2020 $7,321 June 30, 2020 ( 6,607 The Company has been in default on this note since June 2019, fifteen $291,660 10% $9,236 three June 30, 2020 ten 369,445 11 8% November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 11 $470,000 June 30, 2020 485,000 $15,000. $9,641 three June 30, 2020 485,000 June 30, 2020 8% May 7, 2020 On May 7, 2020, $135,000 15,000 $150,000 8.0% first $8,000,000 10 11 8,002,500 $0.04. $272,085 $49,525 $222,560. 150,000 three June 30, 2020 $151,742 $1,742 $150,000 June 30, 2020 $0. Summary of Notes Payable As of June 30, 2020 As of June 30, 2020 Short-Term Notes Payable Face Value Discount Carrying Value 6% Convertible promissory notes payable (Note 6) $ 1,257,000 $ (58,812 ) $ 1,198,188 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (182,276 ) 1,089,587 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 3,041,500 - 3,041,500 0% Note Payable dated October 23, 2017 (Note 5) 369,445 (6,607 ) 362,838 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Note Payable dated May 7, 2020 (Note 5) 150,000 - 150,000 Total Short-Term Notes Payable $ 6,574,808 $ (247,695 ) $ 6,327,113

Note 6 - Convertible Notes

Note 6 - Convertible Notes	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Convertible Debt [Text Block]	Note 6 March 2017 $2M In March 2017, third $1,000 6% 4,000 $0.25 4,000 $0.60 three March 2017 May 2017, $2,000,000. three 8,000,000 8,000,000 one $0.60 three $1,933,693, $904,690 $1,029,003 July 2017 $7.2M In July, 2017, third $1,000 6% 4,000 $0.25 4,000 $0.65 three July 2017 December 2017, $7,201,000. three 28,804,000 28,804,000 one $0.60 three $7,092,796, $3,142,605 3,950,191 As of June 30, 2020 $ 1,198,188 $ ( 58,812 March 2017 July 2017 $228,052. $96,527 three June 30, 2020 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, $1,500,000 8% August 28, 2020 8,823,529 $0.17 100% $176,471 On May 28, 2019, $170,000 8% February 28, 2019. 1,000,000 $0.17 17,225 $152,775. $1,330,000. On July 12, 2019, 8% $100,000 $100,000 July 12, 2019, $41,863 $0.11 We evaluated the modification under the guidance in ASC 470 50 10% $1,338,057, $133,806, $124,158. On August 1, 2019, 110,000 $0.11 1,000,000 $9,579 $100,421. 1,361,863. On October 23, 2019, October 23, 2019 $0.08 We evaluated the modification under the guidance in ASC 470 50 10% 2nd $1,269,067, $92,796, $92,796. On November 27, 2019, 8% “2nd 2nd $0.04 $30,000 We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd no 2nd $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 During the three June 30, 2020 $252,573 $25,367 $227,206 June 30, 2020 1,089,587 ( 182,276 The Company is in default on the amended CSW Note due to non-payment of the quarterly interest payments due on October 1, 2019, January 1, 2020, March 1, 2020, June 1, 2020, March 31, 2018 5 ten 11 8% April 23, 2019 On April 23, 2019, 8% $2,765,000. $265,000 $0.17 April 22, 2020. $440,000 $265,000 $175,000 During the year ended March 31, 2020, $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 On April 22, 2020, 10%. $9,559 10% $276,500 10% June 30, 2020 3,041,500 10% $192,649, $9,559 10% During the three June 30, 2020 $130,659, $29,831 $100,828 8.0% April 22, 2020, 15.0% April 23, 2020 June 30, 2020 On May 20, 2020, not July 14, 2020, $3,264,594 15% not

Note 7 - Capital Transactions

Note 7 - Capital Transactions	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 7 Sale of Common Stock and Exercise of Warrants On April 1, 2020, $0.03 $.05 4,991,084 three June 30, 2020 136,081 ( 15,121 At June 30, 2020 79,547,077 $0.25 $1.00 13,366,334 $0.28

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 8 On September 18, 2017 five two five The contract includes the Company's commitment to make an annual research investments of $500,000 50% 10 $250,000 $500,000 three $750,000. September one August 4, 2020, first $250,000 twelve September 30, 2020, twelve 50% 50% 25% On August 24, 2020, $250,000 no 10 Tara “Dee” Russell filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, May 15, 2019. July 26, 2019. not not On April 22, 2020, 6 10% $286,059 June 30, 2020 $3,234,149 $192,649. On May 20, 2020, not July 14, 2020, $3,264,594 15% not On April 22, 2020, $73,050 $73,050 June 30, 2020 From time to time, the Company may not

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 9 As of June 30, 2020 712,176 $447,633 $109,087 $84,497 $70,959 In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $ 151,923 first 10 August 4, 2020, first 12

Note 10 - Sale of 50% Membershi

Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC	3 Months Ended
	Jun. 30, 2020
GB Sciences Louisiana, LLC, Sale of Equity [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 10 On February 12, 2018, 15% $3 35% 5% $1 $7.0 49.99%. On November 15, 2019, 50.01% $8,000,000 may $8,000,000 On August 24, 2020, $5,224,423, $324,423 $4,900,000 October 15, 2020, $8,000,000 $250,000 8 no $750,000 September 1, 2020 $500,000. $4,900,000 $8,000,000 As a result of the August 24, 2020 March 31, 2020 5,224,423 $1,895,434 March 31, 2020 June 30, 2020 5,224,423 The Company granted forbearance of the June 1, 2020 19 August 4, 2020, $250,000 twelve September 2020 ( 8 5 $189,423 For all periods presented in the unaudited financial statements, the assets, liabilities, income, and cash flows of GBSLA have been reclassified to discontinued operations.

Note 11 - Sale of Membership In

Note 11 - Sale of Membership Interests in Nevada Subsidiaries	3 Months Ended
	Jun. 30, 2020
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 11 On November 15, 2019, 75% $3.0 $3.0 $470,000 5 8% 8% February 28, 2019 ( 6 On March 24, 2020, 100% $4,000,000 $4,000,000 8% 36 On July 24, 2020, 8% "July 24 $500,000 may 8% February 28, 2019 ( 6 July 24 $4,000,000 3 July 24 not July 24 The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada has been subject to an indefinite moratorium since October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company's wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, 100% $300,000

Note 12 - Subsequent Events

Note 12 - Subsequent Events	3 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12 Capital Transactions On July 24, 2020, 8% "July 24 $500,000 may 8% February 28, 2019 ( 6 July 24 $4,000,000 11 3 July 24 not July 24 Note Receivable The Company granted forbearance of the June 1, 2020 19 August 4, 2020, $250,000 10 5 $189,423 On August 24, 2020, $5,224,423, $324,423 $4,900,000 October 15, 2020, $8,000,000 $250,000 10 no $750,000 September 1, 2020 $500,000. $4,900,000 $8,000,000 On August 31, 2020, 30 $500,000 September 1, 2020. October 15, 2020 $4,900,000 August 24, 2020 Litigation On April 22, 2020, 6 10% $286,059 June 30, 2020, $3,234,149 $192,649. On May 20, 2020, not July 14, 2020, $3,264,594 15% not

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2021. March 31, 2020 not 10 March 31, 2020
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the comparative period amounts to conform to the current period presentation. Certain items on the unaudited statements of operations and cash flows have been reclassified to conform with current period presentation. The assets, liabilities, income, and cash flows of GB Sciences Louisiana, LLC have been separated from the comparative period amounts to confirm to the current period presentation as discontinued operations as the result of the sale of the Company's interest in GB Sciences Louisiana, LLC (Note 10 no
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. There were no June 30, 2020 March 31, 2020 The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three June 30, 2020 2019 For the Three Months Ended June 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 551,197 $ - $ 551,197 $ 910,676 $ - $ 910,676 Cost of goods sold (491,795 ) - (491,795 ) (624,369 ) - (624,369 ) Gross profit 59,402 - 59,402 286,307 - 286,307 General and administrative expenses 804,708 - 804,708 2,065,549 201,840 2,267,389 LOSS FROM OPERATIONS (745,306 ) - (745,306 ) (1,779,242 ) (201,840 ) (1,981,082 ) OTHER EXPENSE Interest expense (795,313 ) - (795,313 ) (437,815 ) (62,594 ) (500,409 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense (11,182 ) - (11,182 ) - - - Total other expense (1,092,554 ) - (1,092,554 ) (437,815 ) (62,594 ) (500,409 ) LOSS BEFORE INCOME TAXES (1,837,860 ) - (1,837,860 ) (2,217,057 ) (264,434 ) (2,481,491 ) Income tax expense (8,840 ) - (8,840 ) (57,392 ) - (57,392 ) NET LOSS $ (1,846,700 ) $ - $ (1,846,700 ) $ (2,274,449 ) $ (264,434 ) $ (2,538,883 )
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not No June 30, 2020
Inventory, Policy [Policy Text Block]	Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first
Debt, Policy [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not
Earnings Per Share, Policy [Policy Text Block]	Earnings/(loss) per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 153,412,936 158,404,020 June 30, 2020 March 31, 2020 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Recently Adopted Standards In June 2016, No. 2016 13, 326 2016 13" 326 326 326 2016 13 not not December 15, 2022, In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, April 1, 2020. not All other newly issued accounting pronouncements but not not

Note 1 - Background and Signi_2

Note 1 - Background and Significant Accounting Policies (Tables)	3 Months Ended
	Jun. 30, 2020
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	For the Three Months Ended June 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 551,197 $ - $ 551,197 $ 910,676 $ - $ 910,676 Cost of goods sold (491,795 ) - (491,795 ) (624,369 ) - (624,369 ) Gross profit 59,402 - 59,402 286,307 - 286,307 General and administrative expenses 804,708 - 804,708 2,065,549 201,840 2,267,389 LOSS FROM OPERATIONS (745,306 ) - (745,306 ) (1,779,242 ) (201,840 ) (1,981,082 ) OTHER EXPENSE Interest expense (795,313 ) - (795,313 ) (437,815 ) (62,594 ) (500,409 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense (11,182 ) - (11,182 ) - - - Total other expense (1,092,554 ) - (1,092,554 ) (437,815 ) (62,594 ) (500,409 ) LOSS BEFORE INCOME TAXES (1,837,860 ) - (1,837,860 ) (2,217,057 ) (264,434 ) (2,481,491 ) Income tax expense (8,840 ) - (8,840 ) (57,392 ) - (57,392 ) NET LOSS $ (1,846,700 ) $ - $ (1,846,700 ) $ (2,274,449 ) $ (264,434 ) $ (2,538,883 )

Note 3 - Inventory (Tables)

Note 3 - Inventory (Tables)	3 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2020 March 31, 2020 Raw materials $ 129,133 $ 91,465 Work in progress 923,737 $ 1,166,511 Finished goods 619,491 $ 466,319 Subtotal 1,672,361 1,724,295 Allowance to reduce inventory to net realizable value (126,470 ) (278,456 ) Total inventory, net $ 1,545,891 $ 1,445,839

Note 4 - Leases (Tables)

Note 4 - Leases (Tables)	3 Months Ended
	Jun. 30, 2020
Notes Tables
Operating and Finance Lease Liabilities, Maturity [Table Text Block]	Year Ending Operating March 31, Finance Leases Leases 2021 (9 months) $ 422,801 $ 8,836 2022 544,296 11,779 2023 560,625 11,779 2024 577,444 3,926 2025 594,767 - Thereafter 3,781,101 - Total minimum lease payments 6,481,034 36,320 Less: Amount representing interest (2,835,211 ) (8,242 ) Present value of minimum lease payments 3,645,823 28,078 Less: Current maturities of capital lease obligations (146,211 ) (7,579 ) Long-term capital lease obligations $ 3,499,612 $ 20,499

Note 5 - Notes Payable and Li_2

Note 5 - Notes Payable and Line of Credit (Tables)	3 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Debt [Table Text Block]	As of June 30, 2020 Short-Term Notes Payable Face Value Discount Carrying Value 6% Convertible promissory notes payable (Note 6) $ 1,257,000 $ (58,812 ) $ 1,198,188 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (182,276 ) 1,089,587 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 3,041,500 - 3,041,500 0% Note Payable dated October 23, 2017 (Note 5) 369,445 (6,607 ) 362,838 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Note Payable dated May 7, 2020 (Note 5) 150,000 - 150,000 Total Short-Term Notes Payable $ 6,574,808 $ (247,695 ) $ 6,327,113

Note 1 - Background and Signi_3

Note 1 - Background and Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Aug. 15, 2019	Apr. 08, 2018	Mar. 31, 2018
Common Stock, Shares Authorized (in shares)	600,000,000		600,000,000	600,000,000	400,000,000	250,000,000
Impairment of Long-Lived Assets Held-for-use	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	153,412,936	158,404,020

Note 1 - Background and Signi_4

Note 1 - Background and Significant Accounting Policies - Discontinued Operations (Details) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Sales revenue	$ 551,197	$ 910,676
Cost of goods sold	(491,795)	(624,369)
Gross profit	59,402	286,307
General and administrative expenses	804,708	2,065,549
LOSS FROM OPERATIONS	(745,306)	(1,779,242)
Interest expense	(795,313)	(437,815)
Debt default penalty	(286,059)
Other expense	(11,182)
Total other expense	(1,092,554)	(437,815)
LOSS BEFORE INCOME TAXES	(1,837,860)	(2,217,057)
Income tax expense	(8,840)	(57,392)
Net loss	(1,846,700)	(2,538,883)
Continuing Operations [Member]
Sales revenue	551,197	910,676
Cost of goods sold	(491,795)	(624,369)
Gross profit	59,402	286,307
General and administrative expenses	804,708	2,065,549
LOSS FROM OPERATIONS	(745,306)	(1,779,242)
Interest expense	(795,313)	(437,815)
Debt default penalty	(286,059)
Other expense	(11,182)
Total other expense	(1,092,554)	(437,815)
LOSS BEFORE INCOME TAXES	(1,837,860)	(2,217,057)
Income tax expense	(8,840)	(57,392)
Net loss	(1,846,700)	(2,274,449)
Discontinued Operations [Member]
Sales revenue
Cost of goods sold
Gross profit
General and administrative expenses		201,840
LOSS FROM OPERATIONS		(201,840)
Interest expense		(62,594)
Debt default penalty
Other expense
Total other expense		(62,594)
LOSS BEFORE INCOME TAXES		(264,434)
Income tax expense
Net loss		(264,434)
Segment, Continuing and Discontinued Operations [Member]
Sales revenue	551,197	910,676
Cost of goods sold	(491,795)	(624,369)
Gross profit	59,402	286,307
General and administrative expenses	804,708	2,267,389
LOSS FROM OPERATIONS	(745,306)	(1,981,082)
Interest expense	(795,313)	(500,409)
Debt default penalty	(286,059)
Other expense	(11,182)
Total other expense	(1,092,554)	(500,409)
LOSS BEFORE INCOME TAXES	(1,837,860)	(2,481,491)
Income tax expense	(8,840)	(57,392)
Net loss	$ (1,846,700)	$ (2,538,883)

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance	$ (99,251,168)		$ (97,387,205)
Working Capital Deficit	(5,381,534)		$ 3,884,877
Net Cash Provided by (Used in) Operating Activities, Total	(323,845)	$ (2,631,121)
Cash Provided by (Used in) Operating Activities, Discontinued Operations		$ (883,295)

Note 3 - Inventory - Schedule o

Note 3 - Inventory - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Raw materials	$ 129,133	$ 91,465
Work in progress	923,737	1,166,511
Finished goods	619,491	466,319
Subtotal	1,672,361	1,724,295
Allowance to reduce inventory to net realizable value	(126,470)	(278,456)
Total inventory, net	$ 1,545,891	$ 1,445,839

Note 4 - Leases (Details Textua

Note 4 - Leases (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Apr. 01, 2019
Operating Lease, Right-of-Use Asset	$ 24,684	$ 26,685
Operating Lease, Liability, Total	$ 28,078
Lessee, Operating Lease, Discount Rate	17.00%
Finance Lease Costs	$ 143,599
Finance Lease, Interest Expense	104,924
Finance Lease, Right-of-Use Asset, Amortization	38,675
Operating Lease, Cost	3,243
Operating Lease, Interest Expense	1,242
Operating Lease, Right-of-Use Asset, Amortization Expense	$ 2,001
Minimum [Member]
Lessee, Finance Lease, Discount Rate	10.20%
Maximum [Member]
Lessee, Finance Lease, Discount Rate	11.50%
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			$ 182,624
Operating Lease, Liability, Total			$ 190,173

Note 4 - Leases - Future Minimu

Note 4 - Leases - Future Minimum Lease Payments (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
2021 (9 months), finance leases	$ 422,801
2021 (9 months), operating leases	8,836
2022, finance leases	544,296
2022, operating leases	11,779
2023, finance leases	560,625
2023, operating leases	11,779
2024, finance leases	577,444
2024, operating leases	3,926
2025, finance leases	594,767
2025, operating leases
Thereafter, finance leases	3,781,101
Thereafter, operating leases
Total minimum lease payments, finance leases	6,481,034
Total minimum lease payments, operating leases	36,320
Less: Amount representing interest, finance leases	(2,835,211)
Less: Amount representing interest, operating leases	(8,242)
Present value of minimum lease payments, finance leases	3,645,823
Present value of minimum lease payments, operating leases	28,078
Less: Current maturities of capital lease obligations, finance leases	(146,211)	$ (166,769)
Less: Current maturities of capital lease obligations, operating leases	(7,579)	(7,265)
Finance lease obligations, long term	3,499,612	3,533,090
Operating lease obligations, long term	$ 20,499	$ 22,515

Note 5 - Notes Payable and Li_3

Note 5 - Notes Payable and Line of Credit (Details Textual)	May 07, 2020USD ($)$ / sharesshares	Oct. 23, 2017USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	May 06, 2020USD ($)	Nov. 27, 2019USD ($)	Oct. 23, 2019USD ($)
Proceeds from Lines of Credit, Total				$ 5,000
Payments of Debt Issuance Costs					175,000
Interest Expense, Debt, Excluding Amortization					17,225
Amortization of Debt Discount (Premium)				510,885	$ 200,382
Repriced Preexisting Warrants with Convertible Debt Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	8,002,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.04
Warrants and Rights Outstanding	$ 272,085						$ 49,525
Fair Value Adjustment of Warrants	$ 222,560
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 470,000
Proceeds from Lines of Credit, Total						$ 485,000
Line of Credit Facility, Maximum Borrowing Capacity, Increased						15,000
Interest Payable				9,641		9,641
Long-term Line of Credit, Total				485,000		485,000
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage		0.00%
Debt Instrument, Face Amount		$ 700,000
Debt Instrument, Term (Year)		3 years
Debt Instrument, Present Value				$ 521,067		521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)				20.30%
Debt Instrument, Unamortized Discount, Total				$ 6,607		6,607			$ 178,933
Interest Expense, Debt, Total				7,321
Debt Instrument, Accrued Monthly Payments, Amount				$ 291,660		$ 291,660
Debt Instrument, Debt Default, Interest Rate Penalty				10.00%		10.00%
Debt Instrument, Debt Default, Accrued Interest				$ 9,236		$ 9,236
Days to Cure Breach of Default After Notification From Lender				10		10
Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Face Amount	$ 150,000
Debt Instrument, Unamortized Discount, Total	150,000			$ 0		$ 0
Proceeds from Issuance of Long-term Debt, Net	135,000
Payments of Debt Issuance Costs	$ 15,000
Interest and Debt Expense, Total				151,742
Interest Expense, Debt, Excluding Amortization				1,742
Amortization of Debt Discount (Premium)				$ 150,000
Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member] | Forecast [Member]
Repayments of Long-term Debt, Total			$ 8,000,000,000,000
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License		$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]
Ownership of Licence		100.00%
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]
Ownership of Licence		100.00%

Note 5 - Notes Payable and Li_4

Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020	Apr. 23, 2019
Discount, short-term notes payable
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Face Value, short-term notes payable	$ 1,257,000
Discount, short-term notes payable	(58,812)
Carrying Value, short-term notes payable	1,198,188
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Face Value, short-term notes payable	3,041,500		$ 2,765,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	3,041,500
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Face Value, short-term notes payable	369,445
Discount, short-term notes payable	(6,607)
Carrying Value, short-term notes payable	362,838
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Issued to Investor on May 7, 2020 [Member]
Face Value, short-term notes payable	150,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	150,000
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Face Value, short-term notes payable	1,271,863
Discount, short-term notes payable	(182,276)
Carrying Value, short-term notes payable	1,089,587
Line of Credit [Member]
Face Value, short-term notes payable	485,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	485,000
Promissory Note [Member]
Face Value, short-term notes payable	6,574,808
Discount, short-term notes payable	(247,695)
Carrying Value, short-term notes payable	$ 6,327,113

Note 6 - Convertible Notes (Det

Note 6 - Convertible Notes (Details Textual)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Dec. 16, 2019USD ($)$ / sharesshares	Nov. 27, 2019USD ($)$ / shares	Nov. 18, 2019USD ($)$ / sharesshares	Oct. 30, 2019USD ($)$ / sharesshares	Oct. 23, 2019USD ($)$ / shares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 12, 2019USD ($)$ / shares	May 28, 2019USD ($)$ / sharesshares	Apr. 23, 2019USD ($)$ / shares	Feb. 28, 2019USD ($)$ / shares	Jul. 31, 2017USD ($)$ / shares	Mar. 31, 2017USD ($)$ / shares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)	May 31, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2020USD ($)
Interest Payable, Current															$ 654,760				$ 397,652
Amortization of Debt Discount (Premium)															510,885	$ 200,382
Interest Expense, Debt, Excluding Amortization																$ 17,225
Subsequent Event [Member] | Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty	15.00%
Litigation Settlement, Amount Awarded to Other Party	$ 3,264,594
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares															$ 0.25
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares															$ 1
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants														4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.60			$ 0.60
Warrants and Rights Outstanding, Term (Year)														3 years			3 years
Class of Warrant or Right, Issued (in shares) | shares																	8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																	1
Warrants Related to July 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants													4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares													$ 0.65					$ 0.60
Warrants and Rights Outstanding, Term (Year)																		3 years
Class of Warrant or Right, Issued (in shares) | shares																		28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																		1
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note														$ 1,000
Debt Instrument, Interest Rate, Stated Percentage														6.00%
Debt Instrument, Face Amount																	$ 2,000,000
Debt Instrument, Term (Year)																	3 years
Debt Instrument, Unamortized Discount, Total																	$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature																	904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants																	$ 1,029,003
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments														4,000			8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares														$ 0.25
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note													$ 1,000
Debt Instrument, Face Amount																		$ 7,201,000
Debt Instrument, Term (Year)													3 years					3 years
Debt Instrument, Unamortized Discount, Total															$ 58,812			$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature																		3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants																		$ 3,950,191
Long-term Debt, Gross															1,198,188
Interest Payable, Current															228,052
Amortization of Debt Discount (Premium)															$ 96,527
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments													4,000					28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares													$ 0.25
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage											8.00%				15.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares					$ 0.0375	$ 0.06					$ 0.17
Debt Instrument, Face Amount											$ 2,765,000				$ 3,041,500
Debt Instrument, Unamortized Discount, Total											265,000
Long-term Debt, Gross															3,041,500
Amortization of Debt Discount (Premium)															29,831
Debt Conversion, Original Debt, Amount					$ 50,000	$ 75,000													$ 125,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares					1,333,333	1,250,000
Short-term Debt, Total															3,041,500
Interest Expense, Debt, Total															130,659
Interest Expense, Debt, Excluding Amortization															100,828
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total											440,000
Payments for Brokerage Fees											$ 175,000
Induced Conversion of Convertible Debt Expense						$ 64,706
Debt Instrument, Debt Default, Interest Rate Penalty		10.00%
Debt Instrument, Debt Default, Interest Expense		$ 9,559
Debt Instrument, Debt Default, Principal Expense		$ 276,500
Debt Instrument, Debt Default, Increase in Principal Amount, Percent		10.00%
Interest Payable															192,649
Interest Payable, Default Penalty															9,559
Promissory Note [Member]
Debt Instrument, Face Amount															6,574,808
Short-term Debt, Total															6,327,113
Promissory Note [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage													6.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage				8.00%					8.00%	8.00%		8.00%
Debt Instrument, Face Amount												$ 1,500,000
Debt Instrument, Unamortized Discount, Total			$ 584,842					$ 9,579		$ 17,225					182,276
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 92,796		$ 133,806			$ 176,471
Long-term Debt, Gross			687,021												1,089,587
Amortization of Debt Discount (Premium)			57,551												227,206
Debt Conversion, Original Debt, Amount			120,000					110,000		170,000
Debt Instrument, Increase (Decrease), Net, Total			(62,449)	$ 30,000				(100,421)	100,000	(152,775)
Short-term Debt, Total			$ 1,271,863	1,361,863			1,269,067	$ 1,361,863	1,338,057	$ 1,330,000
Proceeds from Related Party Debt									100,000
Debt Instrument, Increase, Accrued Interest									41,863
Gain (Loss) on Extinguishment of Debt, Total				$ 0			$ (92,796)		$ (124,158)
Interest Expense, Debt, Total															252,573
Interest Expense, Debt, Excluding Amortization															$ 25,367
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Minimum [Member]
Days to Cure Breach of Default After Notification From Lender															5
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Maximum [Member]
Days to Cure Breach of Default After Notification From Lender															10
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent												100.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments												8,823,529
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 0.04	$ 0.04			$ 0.08	$ 0.11	$ 0.11	$ 0.17		$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares			3,000,000					1,000,000		1,000,000

Note 7 - Capital Transactions (

Note 7 - Capital Transactions (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Proceeds from Warrant Exercises	$ 151,202
Class of Warrant or Right, Outstanding (in shares)	79,547,077
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	13,366,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 0.28
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	0.25
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Exercises in Period (in shares)	4,991,084
Proceeds from Warrant Exercises	$ 136,081
Brokerage Fees for Issuance of Common Stock and Warrants	$ 15,121
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.03
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.05

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual)	Aug. 24, 2020USD ($)	Aug. 04, 2020USD ($)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Sep. 18, 2017USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value				$ 73,050
Loss Contingency Accrual, Ending Balance								$ 73,050
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Debt Default, Interest Rate Penalty				10.00%
Debt Instrument, Default, Expense				$ 286,059
Long-term Debt, Total						$ 3,234,149	$ 3,234,149
Interest Payable						$ 192,649	192,649
Subsequent Event [Member] | Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty			15.00%
Litigation Settlement, Amount Awarded to Other Party			$ 3,264,594
Agreement With Louisiana State University AgCenter [Member]
Term of Agreement (Year)					5 years	3 years
Option to Renew Agreement, Amount					2
Term of Agreement, Renewal (Year)					5 years
Research and Development Expense, Total					$ 500,000	$ 250,000	$ 750,000
Agreement With Louisiana State University AgCenter [Member] | Subsequent Event [Member]
Annual Research Contributions	$ 250,000	$ 250,000

Note 9 - Related Party Transa_2

Note 9 - Related Party Transactions (Details Textual) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Notes Payable, Related Parties, Current	$ 151,923	$ 151,923
John Davis [Member]
Notes Payable, Related Parties, Current	151,923
Officers and Directors [Member]
Due to Related Parties, Total	712,176
Unpaid Bonuses, Related Parties	84,497
Reimbursement for Business Expense, Related Parties	70,959
Officer [Member]
Unpaid Wages, Related Parties	447,633
Director [Member]
Unpaid Wages, Related Parties	$ 109,087

Note 10 - Sale of 50% Members_2

Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) - USD ($)	Aug. 24, 2020	Aug. 04, 2020	Nov. 15, 2019	Feb. 12, 2018	Oct. 15, 2020	Mar. 31, 2020	Jun. 30, 2020	Aug. 23, 2020
Subsequent Event [Member] | John Davis [Member]
Due to Related Parties, Total		$ 189,423
Subsequent Event [Member] | Agreement With Louisiana State University AgCenter [Member]
Annual Research Contributions	$ 250,000	$ 250,000
GB Sciences Louisiana, LLC [Member]
Proceeds from Divestiture of Businesses			$ 8,000,000
Earnout Payments			$ 8,000,000
Financing Receivable, after Allowance for Credit Loss, Total						$ 5,224,423	$ 5,224,423
Gain (Loss) on Modification of Note Receivable						$ (1,895,434)
GB Sciences Louisiana, LLC [Member] | Subsequent Event [Member]
Notes Receivable, Net, Scheduled Payments	$ 500,000							$ 750,000
GB Sciences Louisiana, LLC [Member] | Forecast [Member]
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness					$ 5,224,423
Debt Instrument, Decrease, Forgiveness					324,423
Proceeds from Collection of Notes Receivable					4,900,000
Note Receivable Satisfied					8,000,000
Annual Research Contribution Commitment to LSU Assumed by Counter Party					$ 250,000
Wellcana Group, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				49.99%
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership			50.01%	15.00%
Sale of Stock, Consideration Received on Transaction				$ 3,000,000			$ 7,000,000
Sale of Stock, Percentage of Ownership Available For Sale				35.00%
Sale of Stock, Percentage of Available Stock For Sale, Percent to be Sold Per Transaction				5.00%
Sale of Stock, Consideration Received Per Transaction				$ 1,000,000

Note 11 - Sale of Membership _2

Note 11 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) - USD ($)	Mar. 24, 2020	Nov. 27, 2019	Jul. 24, 2020	Dec. 06, 2019
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%
Proceeds from Divestiture of Businesses	$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total	$ 4,000,000
Notes Receivable, Interest Rate	8.00%
Notes Receivable, Term of Monthly Installments (Month)	3 years
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 470,000
Teco Note [Member] | Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 470,000
The July 24 Note [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage			8.00%
The July 24 Note [Member] | Secured Debt [Member] | Subsequent Event [Member] | AJE Management, LLC [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 500,000
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Teco [Member]
Sale of Stock, Percentage of Ownership		75.00%
Sale of Stock, Consideration Received on Transaction		$ 3,000,000
Sale of Stock, Additional Earn-out Payments		$ 3,000,000
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership		100.00%
Sale of Stock, Consideration Received on Transaction		$ 300,000

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)	Aug. 24, 2020	Aug. 04, 2020	Jul. 14, 2020	Apr. 22, 2020	Oct. 15, 2020	Aug. 31, 2020	Aug. 23, 2020	Jul. 24, 2020	Jun. 30, 2020	Apr. 23, 2019
GB Sciences Louisiana, LLC [Member] | Forecast [Member]
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness					$ 5,224,423
Debt Instrument, Decrease, Forgiveness					324,423
Proceeds from Collection of Notes Receivable					4,900,000
Note Receivable Satisfied					8,000,000
Annual Research Contribution Commitment to LSU Assumed by Counter Party					$ 250,000
Subsequent Event [Member] | Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty			15.00%
Litigation Settlement, Amount Awarded to Other Party			$ 3,264,594
Subsequent Event [Member] | GB Sciences Louisiana, LLC [Member]
Notes Receivable, Net, Scheduled Payments	$ 500,000						$ 750,000
Note Receivable, Payments in Forbearance						$ 500,000
Subsequent Event [Member] | John Davis [Member]
Due to Related Parties, Total		$ 189,423
Subsequent Event [Member] | Agreement With Louisiana State University AgCenter [Member]
Annual Research Contributions	$ 250,000	$ 250,000
The July 24 Note [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage								8.00%
July 24 Note [Member] | Subsequent Event [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 500,000
The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage									15.00%	8.00%
Debt Instrument, Debt Default, Interest Rate Penalty				10.00%
Debt Instrument, Default, Expense				$ 286,059
Long-term Debt, Total									$ 3,234,149
Interest Payable									$ 192,649